More recently, compelling evidence supporting the role of the RANKL/RANK pathway in response to immunotherapy [8,9,10] fueled translational and clinical research on the biology and targeting of the RANKL/RANK pathway in cancer. Here, TNFRSF11A is linked to cancer.